Literature DB >> 12644903

Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Tracy M Felton1, Tommy B Kang, Stephan Hjorth, Sidney B Auerbach.   

Abstract

Some clinical reports suggest that tricyclic antidepressants which block both noradrenaline and serotonin (5-HT) reuptake (SNRIs) are more effective than selective 5-HT reuptake inhibitors (SSRIs) in treating severe depression. Moreover, one neurochemical study reported larger increases in extracellular 5-HT in rat frontal cortex in response to the tricyclic antidepressant imipramine compared to the SSRI fluoxetine. However, imipramine, which blocks both 5-HT and noradrenaline reuptake, also binds with relatively high affinity to receptors for noradrenaline, histamine and acetylcholine. Thus, to test the hypothesis that compounds that inhibit both 5-HT and noradrenaline reuptake produce larger increases in 5-HT efflux, we compared the effects of acute systemic administration of several SNRIs and SSRIs. Extracellular 5-HT was measured using microdialysis probes implanted in the diencephalon and frontal cortex of unanesthetized rats. We tested the SSRIs paroxetine (0.3-10 mg/kg), citalopram (10-20 mg/kg) and fluoxetine (10 mg/kg), the nonselective tricyclic antidepressant imipramine (20 mg/kg) and the more selective SNRIs duloxetine (3-30 mg/kg) and venlafaxine (30-50 mg/kg). During the lights-off period, paroxetine and duloxetine increased 5-HT in the diencephalon approximately 300 and approximately 200%, respectively. During the lights-on period, paroxetine and duloxetine each increased 5-HT approximately 400% in the diencephalon. In the frontal cortex, both paroxetine and duloxetine increased 5-HT approximately 200%. Citalopram and venlafaxine each increased 5-HT in the diencephalon approximately 300%. Fluoxetine and imipramine increased 5-HT in the diencephalon by approximately 125 and approximately 80%, respectively. Thus, these results do not support the hypothesis that compared to SSRIs, compounds which inhibit both 5-HT and noradrenaline reuptake have a larger acute effect on extracellular 5-HT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644903     DOI: 10.1007/s00210-002-0688-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935.

Authors:  A Gobert; J M Rivet; L Cistarelli; M J Millan
Journal:  J Neurochem       Date:  1997-03       Impact factor: 5.372

Review 2.  Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis.

Authors:  R W Fuller
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

3.  Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.

Authors:  I Hervás; C M Queiroz; A Adell; F Artigas
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo.

Authors:  E Gur; E Dremencov; B Lerer; M E Newman
Journal:  Eur J Pharmacol       Date:  1999-05-07       Impact factor: 4.432

5.  Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine.

Authors:  J J Rutter; C Gundlah; S B Auerbach
Journal:  Neurosci Lett       Date:  1994-04-25       Impact factor: 3.046

6.  Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.

Authors:  J C Béïque; C de Montigny; P Blier; G Debonnel
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

7.  The comparison of fluoxetine and nisoxetine with tricyclic antidepressants in blocking the neurotoxicity of p-chloroamphetamine and 6-hydroxydopamine in the rat brain.

Authors:  D T Wong; F P Bymaster
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-10

8.  Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo.

Authors:  R Tao; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

9.  LY248686, a new inhibitor of serotonin and norepinephrine uptake.

Authors:  D T Wong; F P Bymaster; D A Mayle; L R Reid; J H Krushinski; D W Robertson
Journal:  Neuropsychopharmacology       Date:  1993-01       Impact factor: 7.853

10.  Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

Authors:  J C Béïque; N Lavoie; C de Montigny; G Debonnel
Journal:  Eur J Pharmacol       Date:  1998-05-15       Impact factor: 4.432

View more
  15 in total

1.  Neonatal administration of buspiron causes changes in intermale aggression of adult mice.

Authors:  N V Markina; O B Shilova; O V Perepelkina; O S Boyarshinova; I B Fedotova; F Z Bizikoeva; I V Gichenok; I I Poletaeva
Journal:  Dokl Biol Sci       Date:  2004 May-Jun

2.  Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Authors:  Szilvia Vas; Zita Kátai; Diána Kostyalik; Dorottya Pap; Eszter Molnár; Péter Petschner; Lajos Kalmár; György Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

3.  Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine.

Authors:  Laurent Naudon; Maïté Hotte; Thérèse M Jay
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

4.  Duloxetine: a new pharmacologic therapy for stress urinary incontinence.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2004

5.  Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.

Authors:  Bríd Aine Nic Dhonnchadha; Nadège Ripoll; Florence Clénet; Martine Hascoët; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

6.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

7.  Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects.

Authors:  A K Larsen; L T Brennum; J Egebjerg; C Sánchez; C Halldin; P H Andersen
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

8.  Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex.

Authors:  Mei Huang; Junji Ichiwaka; Zhu Li; Jin Dai; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

9.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

10.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.